We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine.
Keep posted about
our latest developments
Ksilink is happy to announce the release of its new website. We will keep you informed about news and activities around patient-based drug discovery. Come and visit us on...
Ksilink, joining academic-industry cell imaging consortium to speed patient-based drug discovery and development
Credit : Broad Institute of MIT and Harvard. Human cells imaged using Cell Painting are treated with fluorescent dyes that mark different cellular components, including the...
Ksilink is pleased to share with you this virtual tour of its partner CECS I-Stem with the following message of its founder and scientific director Marc Peschanski: “Dear...
They trust us
“Patient-derived disease models used for phenotypic drug discovery purposes carry a huge potential. We strongly believe in Ksilink as a key player for effectively bridging the gap between scientific excellence and the pharma industry.”
Jacques Volckmann, Head of R&D, Sanofi, France
“Ksilink’s capacities to apply patient-derived disease models for high-throughput, high-content screening by using AI-driven deep learning computation is outstanding.”
Wolfram Zimmermann, CSO, Myriamed GmbH, Germany
“Bridging the gap between academic clinical research and industry is key to enable the precision medicine of tomorrow. We see big value in the ability of Ksilink to translate clinical expertise into treatment for diseases with high unmet medical need .”
Andreas Meyer-Lindenberg, Director and CEO, Central Institute of Mental Health, Germany
“Phenotypic screening using most authentic disease models is clearly paving the way towards next generation medicine. We strongly believe in Ksilink’s potential, allowing the generation of valuable first-in-class therapeutic molecules.”
Bert Klebl, Managing Director of Lead Discovery Center, Germany